MDS Beacon articles – for the latest research and trial updates17 Nov. 2013
The MDS Beacon is a great source of information on MDS.
There you can find the latest research articles – in a language patients can understand.
We used some of their articles in our latest newsletter – but if you’d like to read more, do check their website online:
Campath May Be Effective In Some Patients With Lower-Risk Myelodysplastic Syndromes
A small retrospective study by German researchers suggests that a short course of treatment with the immunosuppressive agent Campath may be safe and effective in patients with lower-risk myelodysplastic syndromes who are good candidates for immunosuppressive therapy.
More on http://www.mdsbeacon.com/news/2013/08/30/campath-lower-risk-myelodysplastic-syndromes/
Half Of MDS Patients With Chromosome 5 Deletion Also Have Important Genetic Mutations
European researchers recently published results of a study looking at genetic mutations in myelodysplastic syndromes patients with a deletion in chromosome 5.
In their study, the researchers focused on 25 genes that often are mutated in patients with myeloid disorders, which include myelodysplastic syndromes (MDS), acute myeloid leukemia, and several other diseases.
More on http://www.mdsbeacon.com/news/2013/10/01/mds-del-5q-chromosome-5-deletion-genetic-mutations/
Zolinza Plus Cytarabine May Be A Good Treatment Option For Higher-Risk MDS Patients Following Vidaza Treatment Failure
Results of a recent Phase 1 clinical trial conducted in France show that treatment with Zolinza and low-dose cytarabine is safe and possibly more effective than current treatment options for higher-risk MDS patients who no longer respond to Vidaza treatment.
More on http://www.mdsbeacon.com/news/2013/10/23/zolinza-vorinostat-cytarabine-after-vidaza-failure-mds/
Do check in regularly.